Skip to content
Blerp – Lifestyle
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Over 40 Studies Featuring Akeso’s Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab’s HARMONi-6 Overall Survival Data Selected for Plenary Session
May 26, 2026
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
May 15, 2026
Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
April 28, 2026
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
April 20, 2026